Bloomberg Daybreak: Europe 05/29/2025
Bloomberg Daybreak Europe is your essential morning viewing to stay ahead. Live from London, we set the agenda for your day, catching you up with overnight markets news from the US and Asia. And we'll tell you what matters for investors in Europe, giving you insight before trading begins. Today's Guests: Benedicte Lowe, equity and derivatives strategist at BNP Paribas Markets 360 (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
42 minutes ago
- Associated Press
Both ISS and Glass Lewis Recommend Shareholders Vote AGAINST Keisei President Toshiya Kobayashi, Endorsing Palliser's Call for Governance Reform
LONDON--(BUSINESS WIRE)--Jun 15, 2025-- Palliser Capital ('Palliser'), one of the largest shareholders of Keisei Electric Railway Co., Ltd. (9009 JT) ('Keisei' or the 'Company') with a shareholding over 4.5%, today welcomed the recommendations by ISS and Glass Lewis that shareholders vote AGAINST the re-election of current President Toshiya Kobayashi and other directors at the Company's upcoming Annual General Meeting on June 27, 2025. Both ISS and Glass Lewis echoed serious concerns with Keisei's governance practices in their research reports, citing: ISS concluded that 'Palliser has made a compelling case that a governance overhaul at Keisei is necessary to restore trust in management', while Glass Lewis concluded that withholding support for Toshiya Kobayashi would serve as a 'measured signal to prompt meaningful improvements in Keisei's governance and transparency practices.' James Smith, Founder and Chief Investment Officer of Palliser, commented: 'ISS and Glass Lewis' recommendations validate our concerns and underscore the importance of holding leadership accountable. We urge shareholders to vote against current President Toshiya Kobayashi, outside directors Shotaro Tochigi, Misao Kikuchi, and Takako Amitani, and proposed new inside directors Kunihiko Yoshikawa and Takeshi Hashimoto.' Full details relating to Palliser's ongoing engagement are available About Palliser Capital Palliser Capital is a global multi-strategy fund. Our value-oriented investment philosophy is applied to a broad range of opportunities across the capital structure with a focus on situations where positive change and value enhancement can be achieved through thoughtful, constructive and long-term engagement with companies and across a range of different stakeholder groups. Palliser Capital is one of the largest Keisei shareholders with a stake in excess of 4.5%. View source version on CONTACT: Media Prosek Partners Brian Schaffer / Kiki Tarkhan / Forrest Gitlin [email protected] KEYWORD: UNITED KINGDOM EUROPE INDUSTRY KEYWORD: RAIL PROFESSIONAL SERVICES TRANSPORT FINANCE SOURCE: Palliser Capital Copyright Business Wire 2025. PUB: 06/15/2025 07:00 PM/DISC: 06/15/2025 07:04 PM
Associated Press
42 minutes ago
- Associated Press
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - June 15, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the 'Class Period'). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025. SO WHAT: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Rocket Pharmaceuticals class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused shareholders to purchase Rocket Pharmaceuticals securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Rocket Pharmaceuticals class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Associated Press
43 minutes ago
- Associated Press
Future of Uncrewed Airpower on Display at Paris Air Show
GA-ASI Features Full-Size Model of New YFQ-42A CCA for Affordable Mass and Air Dominance PARIS, FR / ACCESS Newswire / June 15, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) returns to Paris in 2025 with a variety of new products and concepts highlighting the future of uncrewed airpower at its stand in Hall 3, B-176, beginning June 16. The centerpiece of the exhibit is a full-scale model of GA-ASI's Collaborative Combat Aircraft (CCA), dubbed YFQ-42A by the U.S. Air Force, in its first international showing. 'We're excited to show off the design of our new YFQ-42A CCA at the largest aviation event of the year,' said GA-ASI President David R. Alexander. 'We know the world is paying attention to our CCA development. Ground tests are underway, and we look forward to first flight in the coming weeks, as we once again rewrite the rules of airpower.' The CCA is one of the many products and capabilities showcased by GA-ASI in Paris. Other products the company will highlight include its growing line of unmanned aircraft systems (UAS), including the MQ-9B SkyGuardian® and SeaGuardian®, and the ability to configure the MQ-9B platform with short takeoff and landing (STOL), as well as the development of an Airborne Early Warning (AEW) capability for MQ-9B. The stand will also feature a demonstration of its new release of TacSit-C2®, GA-ASI's tactical situational awareness software for payload Command and Control (C2) that enables operators to plan and execute missions as part of GA's Quadratix software enterprise. About GA-ASI General Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike. For more information, visit Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries. # # # Contact InformationGA-ASI Media Relations (858) 524-8101 SOURCE: General Atomics Aeronautical Systems, Inc. press release
